Veltassa®: A Potent Solution for High Potassium Levels
Veltassa offers enduring and well-received potassium regulation for individuals battling chronic kidney disease and chronic heart failure, with global recognition in 41 countries 1-5.
Zeria Pharmaceutical Co., Ltd. Gets the Green Light
The Ministry of Health and Labor Welfare in Japan has given Zeria Pharmaceutical Co., Ltd. the green light to market Veltassa in the Land of the Rising Sun, marking a significant milestone for the company 6.
A Triumph in the East
“We are delighted with Veltassa’s approval in Japan and extend our congratulations to our esteemed partner, Zeria,” shared Hervé Gisserot, General Manager of CSL Vifor. This approval signifies a joint effort to aid the 300,000+ affected by hyperkalemia in Japan, especially those with chronic kidney disease or heart failure. With this stride, a cutting-edge hyperkalemia management therapy is introduced, poised for widespread adoption across diverse patient demographics.
Setting the Stage: The Journey of Approval
The approval was hinged on the comprehensive marketing authorization submission by Zeria, backed by positive clinical data from the Japanese ZG-801 (Veltassa) clinical program for hyperkalemia patients in Japan.
Partnership Pioneering Progress
In 2018, CSL Vifor granted Zeria the exclusive rights to develop and introduce Veltassa in Japan, with plans for the drug to hit the market following National Health Insurance pricing.
A Glance at Hyperkalemia
Hyperkalemia, an urgency demanding attention, results from elevated potassium levels in the bloodstream, raising concerns primarily in patients battling chronic kidney disease (CKD) and heart failure (HF). Medications like renin-angiotensin aldosterone system inhibitors (RAASi), vital in disease management, could heighten the risk of hyperkalemia 10.
Unveiling the Power of Veltassa®
Veltassa boasts sodium-free characteristics, playing a crucial role as a potassium binder that regulates blood potassium levels. Operating within the gastrointestinal tract by trading potassium for calcium, mainly in the colon, Veltassa aids in expelling excess potassium through regular excretion, enabling patients to manage chronic hyperkalemia while adhering to recommended RAASi dosages effectively. Across multiple placebo-controlled, randomized clinical trials, Veltassa has exhibited the optimization of RAASi therapy in a diverse patient pool 2,3,11.
Celebrating a Global Footprint
Today, in September 2024, Veltassa is accessible in 41 nations globally, including the U.S. and the EU, marking a significant step in the treatment of hyperkalemia across the world.
